Healthcare

● Lumexa Imaging edged up after KeyBanc upgraded the stock to Strong Buy, though the reports reviewed did not include a price target or detailed reasoning.

● ADARx Pharmaceuticals priced an upsized IPO at $17 a share, raising $446.3 million, and shares soared in their first session on theNasdaqComposite.

A 90.5% premarket jump to roughly USD 0.41 is the kind of move that only happens to a stock already trading at a deeply discounted, small-cap valuation, and Accuray fits that description. The catalyst was the announcement of a collaboration with Samsung NeuroLogica focused …

Biofrontera's supplemental new drug application covering Ameluz photodynamic therapy for superficial basal cell carcinoma carried a PDUFA target date of September 28, 2026, the formal deadline by which the FDA had committed to rendering a decision. In practice, the agency moved faster than that …

Eli Lilly's reported interest in committing up to USD 100 million to Oura's initial public offering stands out because it comes from a pharmaceutical giant rather than a traditional tech or healthcare-focused fund. The GLP-1 drug category, which includes weight-loss and diabetes therapies, has …

The biotechnology sector has a busy pre-market session. Late-stage clinical readouts, early-stage efficacy data, government funding, regulatory updates and aMedTechimagingPartnershipare all driving attention. Ophthalmology, autoimmune disease, antifungals, neurology, oncology and metabolic disorders are all represented, showing how varied the catalysts are across small- and …

Monday's pre-market session in small-cap healthcare is being driven largely byCapital Structurenews rather than clinical readouts. Reverse splits,Equityofferings,Warrantwindows andDebtconversions are all in play, alongside one commercialPartnershipand one preclinical data release.